XBIO - Xenetic Biosciences, Inc. News

Xenetic Biosciences Announces That Its Collaboration Partner PeriNess Received Israeli Ministry Of H

This approval follows positive preclinical results that demonstrated significant improvement of CAR

Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israel

Company evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targ

Xenetic Biosciences Reports ASCO 2026 Data Showing DNase I Boosts CAR-T Expansion And Anti-Tumor Act

New preclinical and translational findings position DNase I as a potentially transformative adjunct

Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances

New preclinical and translational findings position DNase I as a potentially transformative adjunct

Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancemen

Advancements across investigator-initiated studies, translational research and manufacturing activit

Xenetic Biosciences Q1 EPS $(0.20) Up From $(0.59) YoY, Sales $806.923K Up From $593.261K YoY

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.20) per share. This is a 66.1 per

Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Mee

FRAMINGHAM, MA / ACCESS Newswire / April 22, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xeneti

Klotho Neurosciences (NASDAQ:KLTO) and Xenetic Biosciences (NASDAQ:XBIO) Head to Head Contrast

Klotho Neurosciences (NASDAQ: KLTO - Get Free Report) and Xenetic Biosciences (NASDAQ: XBIO - Get Fr

12 Health Care Stocks Moving In Friday's Pre-Market Session

Xenetic Biosciences Q4 EPS $(0.22) Beats $(0.52) Estimate, Sales $766.296K Beat $690.000K Estimate

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.22) per share which beat the anal

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in d

Ainos (NASDAQ:AIMD) and Xenetic Biosciences (NASDAQ:XBIO) Head to Head Analysis

Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) and Ainos (NASDAQ: AIMD - Get Free Report) are

Xenetic Biosciences, Inc. (NASDAQ:XBIO) Sees Large Increase in Short Interest

Xenetic Biosciences, Inc. (NASDAQ: XBIO - Get Free Report) was the recipient of a large growth in sh

Critical Contrast: Cumberland Pharmaceuticals (NASDAQ:CPIX) vs. Xenetic Biosciences (NASDAQ:XBIO)

Cumberland Pharmaceuticals (NASDAQ: CPIX - Get Free Report) and Xenetic Biosciences (NASDAQ: XBIO -

Critical Review: Xenetic Biosciences (NASDAQ:XBIO) & Crinetics Pharmaceuticals (NASDAQ:CRNX)

Crinetics Pharmaceuticals (NASDAQ: CRNX - Get Free Report) and Xenetic Biosciences (NASDAQ: XBIO - G

12 Health Care Stocks Moving In Tuesday's After-Market Session

12 Health Care Stocks Moving In Monday's Pre-Market Session

Xenetic Biosciences, Inc. (NASDAQ:XBIO) Sees Large Drop in Short Interest

Xenetic Biosciences, Inc. (NASDAQ: XBIO - Get Free Report) was the recipient of a significant declin

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting

Adjourns 2025 Annual Meeting of Stockholders Urges Stockholders Who Have Not Voted To Get Votes In F

12 Health Care Stocks Moving In Wednesday's After-Market Session

Xenetic Biosciences Executes 4-Month Extension Of Collaboration With Institute Investigator At Scrip

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceu

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with Institute Investigator

FRAMINGHAM, MA / ACCESS Newswire / November 19, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xen

Xenetic Biosciences Q3 EPS $(0.33) Beats $(0.49) Estimate, Sales $1.027M Beat $630.000K Estimate

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.33) per share which beat the anal

Xenetic Biosciences, Inc. Reports Third Quarter 2025 Financial Results

Continued execution on collaborations and exploratory investigator-initiated studies with institutio

Micron, Galecto And Xenetic Lead This Week's Benzinga Stock Ranking Surges

Benzinga Edge Stock Rankings evaluate companies across four key factors. Here are three big companie

12 Health Care Stocks Moving In Friday's Intraday Session

Xenetic Biosciences Prices Offering Of 735K Common Shares At $6.12/Shr For Gross Proceeds Of ~$4.5M

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceu

Xenetic Biosciences, Inc. Announces Pricing of $4.5 Million Underwritten Offering of Common Stock

FRAMINGHAM, MA / ACCESS Newswire / October 10, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xene

4 Stocks In The Same Sector Just Made A Huge Leap In Momentum Rankings

Healthcare and biotech stocks have lagged broader markets this year, but a growing number of names h

Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarke

12 Health Care Stocks Moving In Wednesday's Intraday Session

Nasdaq Gains 150 Points; US Mortgage Applications Decline

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Why Confluent Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket

Xenetic Biosciences Q2 EPS $(0.45) Beats $(0.65) Estimate, Sales $589.897K Miss $720.000K Estimate

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.45) per share which beat the anal

Xenetic Biosciences, Inc. Reports Second Quarter 2025 Financial Results

Expanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studi

zacks.com

Xenetic Biosciences (XBIO) Reports Q2 Loss, Misses Revenue Estimates

Xenetic Biosciences (XBIO) came out with a quarterly loss of $0.45 per share versus the Zacks Consen

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to

Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv S

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research I

Research and development collaboration program to include additional models of lymphoma and leukemia

Xenetic Biosciences Announces First Patient Dosing In Exploratory Clinical Study Of Systemic DNase I

Investigator initiated exploratory clinical study being conducted in Israel pursuant to agreement wi

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Expl

Investigator initiated exploratory clinical study being conducted in Israel pursuant to agreement wi

12 Health Care Stocks Moving In Monday's After-Market Session

12 Health Care Stocks Moving In Monday's After-Market Session

Xenetic Biosciences Q1 EPS $(0.59) Beats $(0.72) Estimate, Sales $593.26K Miss $670.00K Estimate

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.59) per share which beat the anal

HC Wainwright & Co. Reiterates Neutral on Xenetic Biosciencesto Neutral

HC Wainwright & Co. analyst Joseph Pantginis reiterates Xenetic Biosciences (NASDAQ:XBIO) fro

HC Wainwright & Co. Reiterates Neutral on Xenetic Biosciencesto Neutral

HC Wainwright & Co. analyst Joseph Pantginis reiterates Xenetic Biosciences (NASDAQ:XBIO) fro

Xenetic Biosciences Q4 EPS $(0.68) Misses $(0.20) Estimate, Sales $648.82K Beat $230.00K Estimate

Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.68) per share which missed the an

Xenetic Biosciences Net Loss For The Year Ended December 31, 2024 Was ~$4M; Ended The Year With ~$6.

Summary of Financial Results for Fiscal Year 2024Net loss for the year ended December 31, 2024 was a

HC Wainwright & Co. Reiterates Neutral on Xenetic Biosciencesto Neutral

HC Wainwright & Co. analyst Joseph Pantginis reiterates Xenetic Biosciences (NASDAQ:XBIO) fro